Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

VIVUS, Inc. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction.

30 Jun 2011

Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction

Palatin Technologies, Inc. announced today that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment of female sexual dysfunction (FSD).

28 Jun 2011

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

22 Jun 2011

Counselling can help men overcome fears over sexual performance after prostate surgery

Men worried that prostate surgery will automatically mean an end to their sex lives are mistaken and shouldn't be put off seeking medical help, according to experts at The Prostate Centre in London.

18 Jun 2011

VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that the positive results from REVIVE-RP, a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED),will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C.

17 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Female cancer survivors benefit from natural nutritional supplement

A natural nutritional supplement, marketed for the last decade as a sexual aid, has been shown to significantly improve overall quality of life for female cancer survivors, according to researchers at Wake Forest Baptist Medical Center.

7 Jun 2011

Weight loss after bariatric surgery may reverse low testosterone, sexual dysfunction in obese men

Low testosterone levels and symptoms of male sexual dysfunction due to obesity may be reversible with weight loss after bariatric surgery, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion.

1 Jun 2011

Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study

BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.

31 May 2011

Avanafil phase 3 trial in ED following radical prostatectomy meets primary endpoints

VIVUS, Inc. today announced positive results from a phase 3, placebo-controlled clinical trial of the investigational drug avanafil for the treatment of erectile dysfunction in patients following a radical prostatectomy.

25 May 2011

Ampio's common stock to be listed on NASDAQ Capital Market

Ampio Pharmaceuticals, Inc., a clinical stage developer of new uses for previously approved drugs and new molecular entities, announces that its common stock has been approved for listing on the NASDAQ Capital Market.

18 May 2011

Calypso System can precisely deliver radiation in post-prostatectomy patients

Calypso Medical Technologies, Inc., developer of GPS for the Body® technology used for the precise tracking of cancerous tumors during radiation therapy, is exhibiting at the American Urological Association Annual Meeting (booth 4337) and will discuss recent clinical findings suggesting that the Calypso® System can be used to more precisely deliver radiation in post-prostatectomy patients.

16 May 2011

Antares Pharma prices underwritten public offering of common stock

Antares Pharma, Inc. today announced it has priced a firm commitment underwritten public offering of 12,500,000 shares of the Company's common stock at a purchase price of $1.60 per share for an aggregate gross offering amount of $20.0 million.

13 May 2011

Antares Pharma first quarter total revenues increase to $3.6 million

Antares Pharma, Inc. today reported financial and operating results for the first quarter ended March 31, 2011.

9 May 2011

Ampio raises $12.732 million through private placement of common stock

Ampio Pharmaceuticals, Inc. announced today the successful completion of a private placement from which Ampio received gross proceeds of $12.732 million.

20 Apr 2011

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine and GVAX Prostate Cancer Vaccine BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization.

19 Apr 2011

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

New book on women's health and diabetes care

"If there is anything that this disease has done to improve my life, it taught me at a young age how to take care of myself." - Nikki Peterson, 24 years old, diabetes for 14 years.

16 Apr 2011

FDA accepts Teva's NDA filing of Bio-T-Gel for male hypogonadism

BioSante Pharmaceuticals, Inc. today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd.. The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.

15 Apr 2011